Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
作者信息
Wellens Judith, Brann Stephanie, Adams Alex, Marlow Luke, Lindsay James O, Satsangi Jack J
机构信息
Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK; Translational Research for Gastrointestinal Diseases, University Hospitals Leuven, Leuven, Belgium.
Translational Gastro-intestinal Unit, Nuffield Department of Medicine, John Radcliffe Hospital, Oxford OX3 9DU, UK.
出版信息
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):507. doi: 10.1016/S2468-1253(22)00120-0. Epub 2022 Apr 6.
Abstract
摘要
相似文献
1
Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.炎症性肠病患者接种第三剂SARS-CoV-2疫苗的影响因素。
Lancet Gastroenterol Hepatol. 2022 Jun;7(6):507. doi: 10.1016/S2468-1253(22)00120-0. Epub 2022 Apr 6.
2
[SARS-CoV-2 Vaccination for Adult Patients with Inflammatory Bowel Disease: Expert Consensus Statements by KASID].[成人炎症性肠病患者的新型冠状病毒2型疫苗接种：韩国炎症性肠病学会专家共识声明]
Korean J Gastroenterol. 2021 Aug 25;78(2):117-128. doi: 10.4166/kjg.2021.110.
3
Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.加拿大安大略省炎症性肠病患者中 SARS-CoV-2 疫苗第三剂的接种情况。
Lancet Gastroenterol Hepatol. 2022 Apr;7(4):288-289. doi: 10.1016/S2468-1253(22)00054-1. Epub 2022 Feb 23.
4
Serological responses to three doses of SARS-CoV-2 vaccination in inflammatory bowel disease.炎症性肠病患者对三剂严重急性呼吸综合征冠状病毒2疫苗接种的血清学反应。
Gut. 2023 Apr;72(4):802-804. doi: 10.1136/gutjnl-2022-327440. Epub 2022 May 23.
5
SARS-CoV-2 Vaccination in IBD: Past Lessons, Current Evidence, and Future Challenges.SARS-CoV-2 疫苗接种在炎症性肠病中的应用：过去的经验教训、当前的证据和未来的挑战。
J Crohns Colitis. 2021 Aug 2;15(8):1376-1386. doi: 10.1093/ecco-jcc/jjab046.
6
Decrease in uptake of SARS-CoV-2 vaccine in patients with inflammatory bowel disease on intravenous biological therapy.接受静脉生物治疗的炎症性肠病患者对新冠病毒疫苗的接种率下降。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):984-985. doi: 10.1016/S2468-1253(22)00302-8. Epub 2022 Sep 22.
7
SARS-CoV-2 vaccination in IBD: more pros than cons.SARS-CoV-2 疫苗接种在 IBD 中的应用：利大于弊。
Nat Rev Gastroenterol Hepatol. 2021 Apr;18(4):211-213. doi: 10.1038/s41575-021-00420-w.
8
Letter of Reply to "Response to: COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association".致《对〈炎症性肠病患者的新冠疫苗接种意愿与犹豫：意大利炎症性肠病患者协会全国调查中的决定因素分析〉的回应》的回复信
Inflamm Bowel Dis. 2022 Mar 30;28(4):e57-e58. doi: 10.1093/ibd/izab281.
9
SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence.炎症性肠病患者使用不同生物制剂时的 SARS-CoV-2 疫苗接种：通信。
Rev Esp Enferm Dig. 2023 Sep;115(9):531. doi: 10.17235/reed.2023.9347/2022.
10
SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?炎症性肠病免疫抑制患者的新型冠状病毒2型疫苗接种：我们的方法应该改变吗？
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):528-529. doi: 10.1016/S2468-1253(21)00184-9. Epub 2021 May 26.
引用本文的文献
1
A Practical Update on COVID-19 and Inflammatory Bowel Disease: COVID-19 Disease Risk and Vaccine Safety and Efficacy.新型冠状病毒肺炎与炎症性肠病实用最新进展：新型冠状病毒肺炎疾病风险及疫苗安全性与有效性
Gastroenterol Hepatol (N Y). 2024 Feb;20(2):88-97.
2
COVID-19 Immunization Rates in Patients with Inflammatory Bowel Disease Worldwide: A Systematic Review and Meta-Analysis.全球炎症性肠病患者的COVID-19免疫接种率：一项系统评价和荟萃分析
Vaccines (Basel). 2023 Sep 25;11(10):1523. doi: 10.3390/vaccines11101523.
3
COVID-19 vaccine-induced antibody and T-cell responses in immunosuppressed patients with inflammatory bowel disease after the third vaccine dose (VIP): a multicentre, prospective, case-control study.COVID-19 疫苗接种后第三剂后炎症性肠病免疫抑制患者的抗体和 T 细胞反应（VIP）：一项多中心、前瞻性、病例对照研究。
Lancet Gastroenterol Hepatol. 2022 Nov;7(11):1005-1015. doi: 10.1016/S2468-1253(22)00274-6. Epub 2022 Sep 9.
Zotero 插件